<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588922</url>
  </required_header>
  <id_info>
    <org_study_id>GFH009X2101</org_study_id>
    <nct_id>NCT04588922</nct_id>
  </id_info>
  <brief_title>A Study of GFH009 in Patients With Hematologic Malignancies</brief_title>
  <official_title>A Phase I, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent in Patients With Relapsed/Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Genfleet Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfleet Therapeutics (Shanghai) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GFH009 is a potent and highly selective CDK9 inhibitor. The study consists of a dose&#xD;
      escalation and a dose expansion part. The purpose of this study is to investigate the safety&#xD;
      and tolerability of GFH009 in relapsed/refractory hematologic malignancies [acute myeloid&#xD;
      leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and&#xD;
      lymphoma], will also explore the preliminary anti-tumor activities of GFH009 in the studied&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of GFH009: Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>21 days</time_frame>
    <description>The incidence of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of GFH009: adverse events (AEs)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The incidence and severity of all AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter AUC0-t (Area under the plasma concentration-time curve (from zero to the time of the last measurable concentration))</measure>
    <time_frame>approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter AUC0-∞ (Area under the plasma concentration-time curve (from zero to infinity)</measure>
    <time_frame>approximately 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>GFH009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFH009</intervention_name>
    <description>In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the expansion part, patients will be assigned based on tumor type(s).</description>
    <arm_group_label>GFH009</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients with cytological or histologically confirmed relapsed or refractory&#xD;
             hematologic malignancies (AML, CLL/SLL and lymphoma)&#xD;
&#xD;
          2. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) except for patients with Gilbert's&#xD;
             syndrome, who are included if total bilirubin is &lt; 3 × ULN or if direct bilirubin is &lt;&#xD;
             1.5 × ULN.&#xD;
&#xD;
             • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × ULN. For&#xD;
             those with hepatic metastases, AST and ALT ≤ 5 × ULN.&#xD;
&#xD;
          3. Amylase and lipase ≤1.5 × ULN&#xD;
&#xD;
          4. Electrolytes and uric acid levels within normal limits (WNL) or correctable with&#xD;
             medical intervention&#xD;
&#xD;
          5. For women of childbearing potential, must consent to use two highly effective methods&#xD;
             (i.e, total abstinence, placement of an intrauterine device) of contraception during&#xD;
             GFH009 treatment and for an additional 90 days after the last administration of study&#xD;
             drug; Men with a partner of childbearing potential, must consent to use two highly&#xD;
             effective methods of contraception during GFH009 treatment and for an additional 90&#xD;
             days after the last administration of study drug.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients with bulky disease who require cytoreductive therapy.&#xD;
&#xD;
          2. Symptomatic central nervous system metastases or primary lymphoma such as primary CNS&#xD;
             lymphoma, leptomeningeal disease, or spinal cord compression. Patients with&#xD;
             asymptomatic CNS metastases who are radiologically and neurologically stable ≥ 4 weeks&#xD;
             following CNS-directed therapy and are on a stable or decreasing dose of&#xD;
             corticosteroids are eligible for study entry.&#xD;
&#xD;
          3. Severe cardiovascular disease within 6 months of study entry, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Clinically significant heart disease such as congestive heart failure requiring&#xD;
                  treatment (NYHA class III or IV), LVEF &lt; 45% as determined by MUGA scan or&#xD;
                  echocardiogram (ECHO), (if just with historical occasional low LVEF but without&#xD;
                  any symptoms or relevant medical history, and the LVEF at screening is &gt; 45%, the&#xD;
                  subject is eligible), or clinically significant arrythmia.&#xD;
&#xD;
               -  History/evidence of acute coronary syndromes (including myocardial infarction,&#xD;
                  unstable angina, coronary artery bypass graft (CABG), coronary angioplasty, or&#xD;
                  stenting).&#xD;
&#xD;
               -  QTcF ≥ 450 msec on screening ECG.&#xD;
&#xD;
          4. Concurrent malignancy within 5 years (for AML patients, 2 years) prior to entry other&#xD;
             than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of&#xD;
             the skin, basal cell carcinoma, prostate cancer not requiring treatment, ductal&#xD;
             carcinoma in situ of the breast, and superficial non-muscle invasive urothelial&#xD;
             carcinoma (excluding T1 lesions and CIS).&#xD;
&#xD;
          5. Chronic or active hepatitis B or hepatitis C virus infection.&#xD;
&#xD;
          6. History of HIV infection.&#xD;
&#xD;
          7. Concomitant medications that are strong CYP3A4 inhibitors and strong inducers within 7&#xD;
             days of first dose. Avoid consumption of Seville orange (and juice), grapefruit or&#xD;
             grapefruit juice, grapefruit hybrids, pomelos, star citrus fruits or St. John's wort&#xD;
             within 7 days of first dose.&#xD;
&#xD;
          8. Medications that are known to prolong the QT interval are prohibited on this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chang Liu</last_name>
    <phone>+86 21 6882 1388</phone>
    <email>cliu@genfleet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

